A central role for cholesterol metabolism and inflammation during the inhibition of non-alcoholic steatohepatitis with a synthetic PPARα agonist

Kristiaan Wouters(Maastricht University), Ronit Shiri‐Sverdlov(Maastricht University), Dieter Lütjohann(University Hospital Bonn), Patrick J. van Gorp(Maastricht University), Veerle Bieghs(Universitätsklinikum Aachen), Marc van Bilsen(Inserm), Bart Staels(Inserm), Marten H. Hofker(Maastricht University), Anja Kerksiek(University of Bonn)
Chemistry and Physics of Lipids
July 9, 2008
10.1016/j.chemphyslip.2008.05.153
Cited by 0

Related Papers

Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity
|Science|2016|2k
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
|Journal of Hepatology|2014|1.5k
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
|Nature Genetics|2007|1.1k
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
|Journal of Biological Chemistry|1999|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k